About us

Differentiated Approach

Trillions of microorganisms that live on our bodies and inside the body - affect a number of threats to human health, including cancer, diabetes, heart disease and obesity. We can't pass by indifferently seeing the potential to of microbiome-based therapeutics.

Therapy Optimalization

Elucidating the biochemical mechanisms underlying this human supraorganism symbiosis is yielding new therapeutic insights to improve human health, treat disease, and potentially modify human disease risk factors.

Life Changing Medicines

It may be possible to prevent or treat abnormalities of the gut microbiota using modified organisms engineered through genetic or synthetic biology approaches.

Science Commercialisation

We have a drive for rapid translation of our research into regulated, safe and efficacious therapies for patients which can be launched to the market and effectively change the way we treat disease.

Our goal is to improve human health by diagnosing, treating and preventing disease by affecting the human microbiome.



Key elements to achieve this goal are to:


  • Explore the potential of the microbiome-body connection to create a differentiated product portfolio. We believe the microbiome has the potential to impact across a range of disease areas and we are committed to pursuing many opportunities in which our platform has the potential to transform the treatment of a broad range of diseases. Our main focus areas include oncology, respiratory diseases, diabetology (with GDM) and gastroenterology.


  • Commercialize our solutions to advance and scale our platform. We plan to continue to invest in our research across multiple focus areas. Our manufacturing processes are designed to ensure the quality and scalability of our products. We plan to continue to invest in novel methods for process development, manufacturing and formulation for our microbiome-based therapeutics. We plan to leverage the efficiency of our integrated capabilities to accelerate the clinical development of many product candidates.


  • Adequately protect our intellectual property to secure our technology and products. We intend to diligently pursue patent protection for our scientific innovations and to maintain a strong and broad estate of patents and trade secrets in Europe. In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. We protect trade secrets and know-how by establishing confidentiality agreements and intellectual property assignment agreements with our employees, consultants, scientific advisors, contractors and collaborators. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary information by third parties.


  • Actively collaborate to realize the potential of the microbiome. We intend to continue to seek collaborations with Universities, biotech and pharmaceutical companies to realize the value of our broad research and extend the range of our development activities in a timely and cost-effective manner. We plan to commercialize products on our own as well as with valuable collaborators.

What would you say?

We would love to meet up in person to discuss all the microbiome opportunities we have.

Contact us

Passio Human Microbiome, founded in 2016, turns today’s microbiome science into tomorrow’s healthcare solutions. We lead broad microbiome research across a range of therapeutic areas. We are the only microbiome company developing microbiome therapeutic for Gestational Diabetes Mellitus, GDM.

Microbiome consists trillions of bacteria which colonise the human gut. It is crucial in shaping the host immune system & metabolism. The microbiome has 100x as many genes as the human genome and almost 95% of our microbiota is located in the GI tract. What’s interesting, the gut microbiota can weight up to 2 kg and the human body has more microbes than there are stars in the milky way. Moreover, each person has a unique gut microbiota, as individual as a fingerprint and about 90% of disease can be linked in some way back to the gut and health of the microbiome.

Our scientists combine science, translational medicine, and use powerful fields such as genomics, epigenomics, transcriptomics, proteomics, metabolomics and microfiometry, as well as bioinformatics to answer important questions about the microbiome. The aim is to use our strengths and the emerging possibilities of expanding the scope of research related to the microbiome. Our goal is to accelerate the development of microbial-based therapies.